The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for […]readmore
Tags : PlantForm
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded […]readmore
Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug Published: Apr 9, 2021 | Tags: Evotec and Exscientia, Initiate, Human Clinical Trials, Novel, Immuno-Oncology Drug PlantForm Signs […]readmore
Biosimilars
PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop
Shots: The agreement facilitates PlantForm’s collaborations in Brazil to provide affordable, effective cancer drugs to millions of Brazilians The 3yrs. research and development collaboration will culminate in protocols for P-I […]readmore